Zimmer (ZBH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zimmer Biomet (ZBH) reported $1.91 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 1.1%. EPS of $1.81 for the same period compares to $1.94 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.89 billion, representing a surprise of +0.88%. The company delivered an EPS surprise of +2.84%, with the consensus EPS estimate being $1.76.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Zimmer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Sales- Knees- United States: $459 million compared to the $464.68 million average estimate based on four analysts. The reported number represents a change of +0.2% year over year. Net Sales- Hips- United States: $264.30 million compared to the $258.29 million average estimate based on four analysts. The reported number represents a change of +3.7% year over year. Net Sales- Hips- International: $231.50 million versus the four-analyst average estimate of $229.39 million. The reported number represents a year-over-year change of -2%. Net Sales- Knees- International: $333.90 million versus the four-analyst average estimate of $328.76 million. The reported number represents a year-over-year change of +1.2%. Net Sales- International: $795.50 million versus $783.50 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +0.7% change. Net Sales- United States: $1.11 billion versus $1.10 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +1.3% change. Net Sales- Knees: $792.90 million versus the eight-analyst average estimate of $787.14 million. The reported number represents a year-over-year change of +0.6%. Net Sales- Other: $149.90 million compared to the $152.71 million average estimate based on eight analysts. The reported number represents a change of -4.7% year over year. Net Sales- S.E.T: $470.50 million compared to the $460.26 million average estimate based on eight analysts. The reported number represents a change of +4% year over year. Net Sales- Hips: $495.80 million compared to the $488.84 million average estimate based on eight analysts. The reported number represents a change of +0.9% year over year. View all Key Company Metrics for Zimmer here>>>Shares of Zimmer have returned -4.6% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks